Microporous polycaprolactone matrices for drug delivery and tissue engineering: The release behaviour of bioactives having extremes of aqueous solubility

Journal of Drug Delivery Science and Technology

Volumn 20, Issue 3, 2010, Pages 207-212

  Chang, H I ^a   Wang, Y ^a,c   Perrie, Y ^b   Coombes, A G A ^a,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ASTON UNIVERSITY   (United Kingdom)

^c NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Matrix device; Microporous; Ocular delivery; Pilocarpine; Polycaprolactone; Steroids; Tissue engineering

Indexed keywords

ACETONE; DEXAMETHASONE; PHOSPHATE BUFFERED SALINE; PILOCARPINE; POLYCAPROLACTONE; PROGESTERONE; TESTOSTERONE;

AQUEOUS SOLUTION; ARTICLE; DIFFUSION COEFFICIENT; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; HYDROPHILICITY; HYDROPHOBICITY; KINETICS; MODEL; MOLECULE; POROSITY; POWDER; PRECIPITATION; TEMPERATURE; TISSUE ENGINEERING;

EID: 77953841432     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(10)50031-5     Document Type: Article

References (32)

1. Croxatto H.B. - Progestin implants. - Steroids, 65, 681-685, 2000.
2. Andersson T.L., Stehle B., Davidsson B., Hoglund P. - Drug concentration effect relationship of estradiol from two matrix transdermal delivery systems:Menorest and Climara. - Maturitas, 35, 245-252, 2000.
3. Delmas P.D., Pornel B., Felsenberg D., Garnero P., Hardy P., Pilate C., Dain M.P. - A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. - International Study Group, Bone, 24, 517-523, 1999.
4. Asthana S., Craft S., Baker L.D., Raskind M.A., Birnbaum R.S., Lofgreen C.P., Veith R.C., Plymate S.R. - Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. - Psychoneuroendocrinology, 24, 657-677, 1999.
5. Sipos E.P., Tyler B., Piantadosi S., Burger P.C., Brem H. - Optimizing interestitial delivery of BCNU from controlled release polymers for the treatment of brain tumours. - Cancer Chemother. Pharmacol., 39, 383-389, 1997.
6. Whitaker M.J., Quirk R.A., Howdle S.M., Shakesheff K.M. - Growth factor release from tissue engineering scaffolds. - J. Pharm. Pharmacol., 53, 1427-1437, 2001.
7. Nicolazzo J.A., Morgan T.M., Reed B.L., Finnin B.C. - Synergistic enhancement of testosterone transdermal delivery. - J. Control. Rel., 103, 577-585, 2005.
8. Williamson M.R., Chang H.I., Coombes A.G. - Gravity spun polycaprolactone fibres: controlling release of a hydrophilic macromolecule (ovalbumin) and a lipophilic drug (progesterone). - Biomater., 25, 5053-5060, 2004.
9. Lin S., Chao P.Y., Chien Y.W., Sayani A., Kuma S., Mason M., Wes T., Yang A., Monkhouse D. - In vitro and in vivo evaluations of biodegradable implants for hormone replacement therapy. Effect of system design and PK-PD relationship. - AAPS PharmSciTech., 2, Article 16, 1-11, 2001.
10. Chang H.I., Williamson M.R., Perrie Y., Coombes A.G. - Precipitation casting of drug-loaded microporous PCL matrices: incorporation of progesterone by co-dissolution. - J. Control. Rel., 106, 263-272, 2005.
11. Pitt C.G., Gratzl M.M., Jeffcoat A.R., Zweidinger R.A., Schindler A. - Sustained drug delivery systems II: factors affecting release rates from polycaprolactone and related biodegradable polyesters. - J. Pharm. Sci., 68, 1534-1538, 1979.
12. Darney P.D. - Hormonal implants: contraception for a new century. - Am. J. Obstetrics & Gynecology, 170, 1536-1543, 1994.
13. Chang H.I., Perrie Y., Coombes A.G. - Delivery of the antibiotic gentamicin sulphate from precipitation cast matrices of polycaprolactone. - J. Control. Rel., 110, 414-421, 2006.
14. Zurowska-Pryczkowska K., Sznitowska M., Janicki S. - Studies on the effect of pilocarpine incorporation into a submicron emulsion on the stability of the drug and the vehicle. - Eur. J. Pharm. Biopharm., 47, 255-260, 1999.
15. Saettone M., Pagano A., Giannaccini B., Rodrguez L., Cini M. - Controlled release of pilocarpine from coated polymeric opthalmic inserts prepared by extrusion. - Int. J. Pharm., 86, 159-166, 1992.
16. Simamora P., Nadkarni S.R., Lee Y.-C., Yalkowski S.H. - Controlled delivery of pilocarpine. 2. In vivo evaluation of Gelfoam device. - Int. J. Pharm., 170, 209-214, 1998.
17. Zimmerman T.J., Wheeler T.M. - Miotics: side effects and ways to avoid them. - Ophthalmology, 89, 76-80, 1982.
18. Marchal-Heussler L., Sirbat D., Hoffman M., Maincent P. - Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery. - Pharm. Res., 10, 386-390, 1993.
19. Yoon J.J., Kim J.H., Park T.G. - Dexamethasone-releasing biodegradable polymer scaffolds fabricated by a gas-foaming/salt-leaching method. - Biomater., 24, 2323-2329, 2003.
20. Coombes A.G., Rizzi S.C., Williamson M., Barralet J.E., Downes S., Wallace W.A. - Precipitation casting of polycaprolactone for applications in tissue engineering and drug delivery. - Biomater., 25, 315-325, 2004. (Pubitemid 37329721)
21. Pryczkowska K.Z., Sznitowska M., Janicki S. - Studies on the effect of pilocarpine incorporation into a submicron emulsion on the stability of the drug and the vehicle. - Eur. J. Pharm. Biopharm., 47, 255-260, 1999.
22. Costa P., Sousa Lobo J.M. - Modeling and comparison of dissolution profiles. - Eur. J. Pharm. Sci., 13, 123-133, 2001.
23. Pitt C.G. - Poly(e-caprolactone) and its copolymers. - In: Biodegradable Polymers as Drug Delivery Systems, Chasin L.R., Langer R., Eds., Marcel Dekker, New York, 1990.
24. Baeyens V., Kaltsatos V., Boisrame B., Varesio E., Veuthey J.L., Fathi M., Balant L.P., Gex-Fabry M., Gurny R. - Optimized release of dexamethasone and gentamicin from a soluble ocular insert for the treatment of external ophthalmic infections. - J. Control. Rel., 52, 215-220, 1998.
25. Erickson G.R., Gimble J.M., Franklin D.M., Rice H.E., Awad H., Guilak F. - Chondrogenic potential of adipose tissue-derived stromal cells in vitro and in vivo. - Biochem. Biophys. Res. Commun., 290, 763-769, 2002.
26. Martin I., Shastri V.P., Padera R.F., Yang J., Mackay A.J., Langer R., Vunjak-Novakovic G., Freed L.E. - Selective differentiation of mammalian bone marrow stromal cells cultured on three-dimensional polymer foams. - J. Biomed. Mater. Res., 55, 229-235, 2001.
27. Montjovent M.-O., Burri N., Silke M., Federici E., Scalefta C., Zambelli P.-Y., Hohlfield P., Leyvraz P.-F., Applegate L.L., Pioletti D.P. - Fetal bone cells for tissue engineering. - Bone, 35, 1323-1333, 2004. (Pubitemid 40260395)
28. Hodge B.O., Kream B.E. - Variable effects of dexamethasone on protein synthesis in clonal rat osteosarcoma cells. - Endocrinology, 122, 2127-2133, 1988.
29. Fromigue O., Marie P.J., Lomri A. - Differential effects of transforming growth factor beta2,dexamethasone and 1,25-dihydroxyvitamin D on human bone marrow stromal cells. - Cytokine, 9, 613-623, 1997. (Pubitemid 27348176)
30. Rosenberg R., Devenney W., Siegel S., Dan N. - Anomalous release of hydrophilic drugs from poly(epsilon-caprolactone) matrices. - Molecular Pharmaceutics, 4, 943-948, 2007.
31. Miyazaki S., Suzuki S., Kawasaki N., Endo K., Takahashi A., Attwood D. - In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. - Int. J. Pharm., 229, 29-36, 2001.
32. Dumitriu S., Vancea P., Costin D., Popa M. - Bioactive polymers. XXXIX. Retarded ophthalmic drugs based on pilocarpine and xanthan derivatives. - Clinical Materials, 2, 141-152, 1987.